ArticleContact dermatitis2026
Patch Testing in Individuals With Diabetes Using Medical Devices. Part 1-Contact Allergy to Baseline Series Allergens.
Article in Contact dermatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe prevalence of contact allergy in individuals with diabetes and diabetes medical device (MD) users is unknown.
objectivesThis study (Part 1 and 2) aims at describing contact allergy prevalences in diabetes MD users.
methodsAdults with type 1 diabetes from two endocrinology departments were patch tested with the Swedish baseline series (SBS) and a MD series. Contact allergies to the baseline series were compared with consecutive dermatitis patients. Detailed results for the MD series are presented in another manuscript.
resultsOverall, similar contact allergy prevalences to the SBS were seen in the 204 individuals with diabetes (114 with rash to diabetes MDs, 90 without) and 1382 controls (34.3% vs. 39.6%, adjusted p value = 0.30). The prevalence of sesquiterpene lactone mix allergy was higher in the individuals with diabetes vs. dermatitis controls (2.5% vs. 0.3%, adjusted p value = 0.0011). Contact allergy to Myroxylon pereirae resin (MP) was overrepresented in individuals with diabetes versus controls (8.3% vs. 3.8%, adjusted p value = 0.0033) but not in individuals with diabetes with rash to diabetes MDs vs. without.
conclusionsContact allergy to the SBS is common in diabetes MD users. The cause of the overrepresentation of MP allergy needs to be further elucidated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.